Category

News

PamGene, Alithea Genomics and Lausanne University Hospital (CHUV) secure Eurostars funding to develop a first-of-a-kind pan-cancer blood test for the prediction of immunotherapy efficacy and toxicity

‘s-Hertogenbosch, the Netherlands; Lausanne, Switzerland – January 17, 2023 MAINLINE, a Dutch-Swiss consortium between PamGene International B.V., Alithea Genomics SA and Lausanne University Hospital (CHUV), has been awarded a Eurostars...
Read More

PamGene announces results of its IOpener®-NSCLC test to predict response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer at the 2022 ESMO Immuno-Oncology meeting in Geneva, Switzerland

‘s-Hertogenbosch, the Netherlands, December 1, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, will present the results of its IOpener®-NSCLC test on...
Read More

PamGene attains IVDD registration for its IOpener®-NSCLC immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 21, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-NSCLC test has been registered as...
Read More

PamGene attains IVDD registration for its IOpener®-melanoma immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 5th, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-melanoma test has been registered as...
Read More

PamGene receives ISO 13485:2016 from DEKRA Certification B.V. for its IOpener® immunotherapy response prediction test devices

‘s-Hertogenbosch, the Netherlands, March 29th, 2022 PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy response prediction tests, today announced it has received...
Read More

Meet our specialists – Savithri Rangarajan

“Making the most out of kinase activity data to take scientific research to the next level is what gets me excited” PamGene’s kinase activity profiling data provides scientists with new...
Read More

Review paper: The past and current trends of kinase research and use of high-throughput active kinome technologies

Recently the University of Toledo published a review paper in ‘The current opinion in pharmacology’. In this review, the authors examine the past and current trends of kinase research and...
Read More

Meet our specialists – Frank de Bruijn

The PamStation is at the core of PamGene’s technology. This fully automated instrument is designed for processing PamChip microarrays to measure kinase activity and can be found at universities worldwide....
Read More

Jointly advancing mutation-independent treatment of inherited retinal diseases

transMed is an integrated training network funded by the European Union to train the next generation of scientists in translational medicine. The consortium focuses on bench-to-bedside development of treatments for...
Read More

Meet our specialists | Unraveling disease mechanisms

“My work at PamGene has always been data driven,” tells Rik de Wijn, data scientist and PamGene’s head of diagnostic assay services. De Wijn joined Pamgene in 2002 after completing...
Read More
1 2 3 4 5